Fig 1.
Incremental net monetary benefit (NMB) of a device as a function of disease prevalence.
In Blue there is a variation of incremental net monetary benefit by an increase in diagnostic accuracy (blue). In red a variation in incremental net monetary benefit generated by an increase in cost. Source: Phelps, C.E. and A.I. Mushlin, 1988. [16].
Fig 2.
Decision trees for Malaria (A) and Schistosomiasis (B).
The end point of panel B fed into decision tree A.
Table 1.
Main Model parameters.
Table 2.
Net Monetary Benefit and Expected Value of Clinical Information referring on Schistosomiasis only arm, for general Schistosomiasis prevalence in rural Uganda.
Fig 3.
Incremental Net Monetary benefit for every comparison across the two outcomes: DALY averted (left) and Correct treatment Schistosomiasis (right). Row represents different perspectives: schistosomiasis only (A), Schistosomiasis and Malaria (B), Representation of incremental NMB of the prototype device as function of both schistosomiasis and malaria (C). Red dashed lines represent relevant prevalence levels of schistosomiasis and malaria for the rural Ugandan context. Dark blue lines represent the prototype device (comparator 3), dotted and dashed lines represent no cost savings (comparator1) and cost savings with current diagnostics (compartor2), respectively.
Table 3.
Net Monetary Benefit and Expected Value of Clinical Information referring on both schistosomiasis and malaria, for general Schistosomiasis and prevalence of Malaria cases among febrile patients at clinics in rural Uganda.
Fig 4.
Representation of the first scenario on economies of scale for cost per DALY averted (left) and cost per correct diagnosis (right) across comparators. Colours represents different strategies: mild red (MDA-treat no one-), dark red (MDA -treat all-), blue (sentinel test).
Fig 5.
Representation of the other alternative scenarios for both the outcomes.
Red dashed vertical line is in correspondence to the relevant values of prevalence for rural Uganda. Dark blue lines represent the prototype device (comparator 3), dotted and dashed lines represent no cost savings (comparator1) and cost savings with current diagnostics (compartor2), respectively.